CANNRA Responds to FDA Announcement, Urges comprehensive regulatory framework

The Cannabis Regulators Association (CANNRA) looks forward to FDA’s work with Congress to develop a regulatory pathway for CBD. While CBD is largely the focus of today’s announcement, CANNRA feels strongly that clarity is urgently needed on a more comprehensive regulatory pathway that addresses the growing number of cannabinoid products (many of which are intoxicating) that are being chemically and synthetically derived from hemp and CBD, including cannabinoids like Delta-8-THC, Delta-10-THC, HHC, and THC-O-Acetates. These types of products pose a myriad of consumer safety and public health risks and create challenges for state cannabis and hemp regulators because they largely fall outside of any current federal regulation.

To read the full press release, click on the image below.